Antonio et al. reported that systemic treatment with G-CSF induces expansion of myeloid cells displaying the phenotype of M-MDSCs (Linlow/negHLA-DR−CD11b+CD33+CD14+), which is the only graft parameter to predict acute GVHD (aGVHD) [25]. The gene discussed is CSF3; the disease is acute graft versus host disease.